Many disease-relevant proteins function through liquid–liquid phase separation, forming biomolecular condensates that are not amenable to conventional small‑molecule inhibition. This “undruggable” biology limits therapeutic options for cancers, neurodegenerative disorders, and other complex conditions. Existing drug discovery pipelines lack tools to quantitatively assess and modulate condensate dynamics in a drug‑like context.
Funding
$59.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many disease-relevant proteins function through liquid–liquid phase separation, forming biomolecular condensates that are not amenable to conventional small‑molecule inhibition. This “undruggable” biology limits therapeutic options for cancers, neurodegenerative disorders, and other complex conditions. Existing drug discovery pipelines lack tools to quantitatively assess and modulate condensate dynamics in a drug‑like context.
Solution
Dewpoint Therapeutics applies a condensate‑centric drug discovery platform that integrates biophysical characterization, computational modeling, and medicinal chemistry to target phase‑separation mechanisms. By quantifying condensate formation, dissolution, and material properties, the platform identifies small‑molecule modulators that can reshape or disrupt pathogenic condensates. Lead compounds are optimized for potency, selectivity, and drug‑like pharmacokinetics using structure‑activity relationship (SAR) cycles informed by condensate assays. The resulting therapeutics aim to intervene in disease pathways that were previously inaccessible to traditional target‑based approaches, expanding the addressable space for oncology and neurodegeneration programs.
Target Audience
Primary customers are pharmaceutical and biotech R&D organizations seeking to expand their pipeline into phase‑separation targets, as well as academic research groups focused on mechanistic studies of condensate biology in cancer and neurodegenerative disease.
Features
- High‑throughput microfluidic assay suite for real‑time measurement of condensate nucleation, growth, and dissolution kinetics
- Atomistic and coarse‑grained molecular dynamics simulations to predict phase‑separation propensity and ligand binding hotspots
- Integrated fragment‑based screening pipeline coupled with label‑free optical readouts (e.g., fluorescence recovery after photobleaching, turbidity)
- Proprietary chemoinformatics platform that maps small‑molecule physicochemical properties to condensate modulation efficacy
- Automated SAR workflow linking biophysical readouts to medicinal chemistry design cycles
- In‑cell condensate imaging using CRISPR‑tagged endogenous proteins and live‑cell confocal microscopy for target validation
- Scalable GMP‑compatible synthesis route for lead optimization and preclinical candidate production